CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
How is CancerIQ working to make genetic services more practical in predicting or preventing cancer?
So, CancerIQ is making it more practical to start predicting and pre-empting cancer by really trying to reduce some of the barriers that are really holding the industry back today. The first of those challenges is really knowledge. You know, to connect the dots on people’s family history, and their genetic testing information. Really stuff that the provider can’t do with the naked eye. So, it’s really through our software that we can automate the decisions that need to be made on the basis of that information, and make it relatively easy for the physician, who, quite frankly, didn’t study genetics when they were in medical school.
The second way that CancerIQ makes it practical for people to do this in routine care is being really mindful of the clinical workflow. Unfortunately, people are today using systems that are primarily oriented for billing and logging of information. And CancerIQ works really well with those systems in being a layer of intelligence on top of that. So, how we actually integrate into your everyday clinical workflow is really connecting to the systems that already exist but putting that layer of intelligence on top of it.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More